Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-672/ECHO-307 pembrolizumab plus epacadostat versus pembrolizumab plus placebo in cisplatin-ineligible urothelial carcinoma
2017-002311-34Phase 3Completed
- Sponsor
- Incyte
- Start
- Oct 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transitional cell carcinoma (TCC) and bladder cancer comparing Pembrolizumab + epacadostat with Pembrolizumab + placebo (2 arms). Primary endpoint: Objective response rate. Started Oct 2017; status: completed.
02
Drugs
pembrolizumabepacadostat
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on 2017-002311-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002311-34.